Danaher Acquires Masimo for $180 Per Share
Masimo Corporation, a prominent medical innovator, has announced a definitive agreement for Danaher Corporation to acquire it for $180 per share in cash. This agreement reflects a total transaction value of approximately $9.9 billion. Both companies’ Boards of Directors have unanimously approved this acquisition.
Details of the Acquisition
Danaher will integrate Masimo as a standalone business unit within its Diagnostics segment. This acquisition aims to enhance Danaher’s offerings in the acute care sector while allowing Masimo to operate independently.
Katie Szyman, Masimo’s CEO, expressed enthusiasm for joining Danaher, emphasizing their mutual commitment to innovation and talent investment. She stated that the merger will accelerate Masimo’s mission to improve patient monitoring solutions globally.
Michelle Brennan, Chairman of Masimo’s Board, commented on the transaction as a unique opportunity to provide significant value for shareholders and enhance patient outcomes. After evaluating various strategic options, the Board determined that partnering with Danaher presented the most beneficial path forward for all stakeholders.
Next Steps and Timeline
The completion of this transaction is subject to certain closing conditions, including necessary regulatory approvals. The deal is expected to finalize in the second half of 2026. In light of this transaction, Masimo will not hold an earnings conference call for the fourth quarter and full-year 2025 results, which are scheduled to be reported on February 26, 2026.
Advisors Involved
- Centerview Partners LLC: Financial Advisor to Masimo
- Morgan Stanley & Co. LLC: Financial Advisor to Masimo
- Sullivan & Cromwell LLP: Legal Advisor to Masimo
- White & Case LLP: Legal Advisor to Masimo
- Longacre Square Partners: Strategy and Communications Advisor to Masimo
About Masimo
Masimo (NASDAQ: MASI) is known for its innovative medical technology, particularly in monitoring solutions. It develops a variety of products aimed at improving patient outcomes through non-invasive monitoring technologies. Masimo’s SET® pulse oximetry technology is utilized globally, with over 200 million patients benefitting from it annually.
As the healthcare landscape evolves, the acquisition by Danaher potentially positions both companies to better address growing market demands and enhance clinical outcomes.
